Selected article for: "cell damage and host cell"
Author: Bhatt, Kinal; Garimella, Radhika; Taugir, Rahima; Mehta, Isha; Jamal, Muhammad; Vijayan, Rupalakshmi; Offor, Rita; Nwankwo, Kanayo; Arif, Uroosa; Waheed, Khurram; Kumari, Priyanka; Lathiya, Maulik; Michel, George; Pandya, Naushira; Halpern, John; Nasir, Hassan; Sanchez-Gonzalez, Marcos A.
Title: Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review
  • Cord-id: b5eanzvj
  • Document date: 2021_3_11
    • ID: b5eanzvj
    Snippet: Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening
    Document: Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications. Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses. The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and adaptive immune response: 1, 2, 3
    • action mechanism and long term efficacy: 1, 2, 3, 4, 5, 6
    • action mechanism and lung damage: 1, 2, 3, 4, 5, 6
    • activation recruitment and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • activation recruitment and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activation recruitment and adaptive immune response: 1, 2, 3, 4
    • activator transducer and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • activator transducer and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • activator transducer and adaptive immune response: 1, 2, 3, 4
    • activator transducer and long term efficacy: 1
    • activator transducer and lung damage: 1, 2
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and admission patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and low mortality rate: 1, 2, 3, 4, 5
    • acute respiratory distress and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25